Compare Cytokinetics Inc (CYTK) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs D Wave Quantum Inc — how do they compare? Cytokinetics Inc trades at $81.92 (market cap $11.12B), while D Wave Quantum Inc trades at $17.98 (market cap $7.02B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | QBTS | |
|---|---|---|
Market Cap | $11.12B | $7.02B |
Sector | Technology | Technology |
52-Week High | $87.26 | $44.78 |
52-Week Low | $33.23 | $12.98 |
Enterprise Value | $11.59B | $6.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
QBTS trades at $18.67, down 7.05% today amid a broader quantum computing sector sell-off. The stock exhibits a bearish technical signal despite oversold RSI readings, while fundamentals reveal severe losses with a net income margin of -2,957.23% and negative cash flow from operations. Recent news highlights its Nasdaq listing transfer and IDC MarketScape recognition as a quantum computing leader.
Analyst consensus remains strongly bullish with a $39.86 price target, but the stock faces significant execution risks, cash burn, and intense competition. Investment appeal hinges on speculative growth in commercial quantum adoption, yet profitability remains distant, demanding high risk tolerance from investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
